DOI: 10.3928/23258160-20260930-02 ISSN: 2325-8160

Outcomes of Diabetic Macular Edema After Switching From Faricimab-svoa to High-dose Aflibercept

Irene P. Kim, Bita Momenaei, Paige Abril, Rachel McCullough, Roselind L. Ni, Mansi J. Shah, Michael A. Klufas, Mitchell S. Fineman, Yoshihiro Yonekawa, Ashkan M. Abbey
Show PDF Cite

Background and Objective:

The purpose of this study was to evaluate the efficacy of high-dose aflibercept 8 mg in the treatment of diabetic macular edema (DME) refractory to faricimab-svoa treatment.

Patients and Methods:

This retrospective study included 82 eyes from 64 patients with DME previously treated with faricimab-svoa. Injection intervals, corrected or pinhole visual acuity (VA), and central foveal thickness (CFT) were recorded.

Results:

Between the time of switch to the fifth injection, the average (SD) injection interval increased from 63 (45) days to 69 (23) days ( P = .01). Mean VA decreased from 58.1 (23.1) to 52.9 (22.7) letters ( P = .263), and average CFT decreased from 360 (145) µm to 348 (151) µm ( P = .626). Intraretinal fluid incidence decreased from 50% to 33.3% ( P = .066), while subretinal fluid incidence increased from 6.1% to 14.8% ( P = .308).

Conclusion:

Anatomic and visual changes were not significant following switch to aflibercept 8 mg. Sustained injection interval improvements were present at the final aflibercept 8 mg injection.

More from our Archive